Dual Targeting of DNA Gyrase and Topoisomerase IV: Target Interactions of Heteroaryl Isothiazolones in Staphylococcus aureus

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2007-05-14

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1128/AAC.00158-07PMID 17502409PMCID PMC1913236
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In Vitro and In Vivo Antibacterial Activities of Heteroaryl Isothiazolones against Resistant Gram-Positive Pathogens

  2007cited by this paper
• NorC, a New Efflux Pump Regulated by MgrA of Staphylococcus aureus

  2006cited by this paper
• Role of the Extended α4 Domain of Staphylococcus aureus Gyrase A Protein in Determining Low Sensitivity to Quinolones

  2006cited by this paper
• Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : Approved standard

  2006cited by this paper
• Methicillin-resistant S. aureus infections among patients in the emergency department.

  2006cited by this paper
• Antimicrobial resistance in gram-positive bacteria.

  2006cited by this paper
• Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus

  2006cited by this paper
• Antimicrobial-resistant bacteria in the community setting

  2006cited by this paper
• Treatment Failure Resulting from Resistance of Staphylococcus aureus to Daptomycin

  2006cited by this paper
• MRSA extends its reach.

  2006cited by this paper
• An improved expression plasmid for affinity purification of Staphylococcus aureus gyrase A subunit.

  2006cited by this paper
• Antibiotic Resistance: A Survival Strategy

  2005cited by this paper
• Susceptibility and resistance genes to fluoroquinolones in methicillin-resistant Staphylococcus aureus isolated in 2002.

  2005cited by this paper
• Mechanisms of action of newer antibiotics for Gram-positive pathogens.

  2005cited by this paper
• The clinical significance of methicillin-resistant Staphylococcus aureus.

  2005cited by this paper
• Clinical impact and relevance of antibiotic resistance.

  2005cited by this paper
• The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae.

  2005cited by this paper
• MgrA Is a Multiple Regulator of Two New Efflux Pumps in Staphylococcus aureus

  2005cited by this paper
• The need for new therapeutic agents: what is the pipeline?

  2005cited by this paper
• Clinical characteristics of linezolid-resistant Staphylococcus aureus infections.

  2005cited by this paper
• Characterization of NorR Protein, a Multifunctional Regulator of norA Expression in Staphylococcus aureus

  2003cited by this paper
• Activity of and Resistance to Moxifloxacin in Staphylococcus aureus

  2003influential reference
• Topoisomerase Targeting with and Resistance to Gemifloxacin in Staphylococcus aureus

  2003influential reference
• Selection of moxifloxacin-resistant Staphylococcus aureus compared with five other fluoroquinolones.

  2003cited by this paper
• Mutant Prevention Concentration of Garenoxacin (BMS-284756) for Ciprofloxacin-Susceptible or -Resistant Staphylococcus aureus

  2003cited by this paper
• Detection of mutations in quinolone resistance-determining regions in levofloxacin- and methicillin-resistant Staphylococcus aureus: effects of the mutations on fluoroquinolone MICs.

  2003cited by this paper
• Activity of BMS-284756, a Novel Des-Fluoro(6) Quinolone, against Staphylococcus aureus, Including Contributions of Mutations to Quinolone Resistance

  2002cited by this paper
• Fluoroquinolone resistance among Gram-positive cocci.

  2002cited by this paper
• Non-fluorinated quinolones (NFQs): new antibacterials with unique properties against quinolone-resistant gram-positive pathogens.

  2002cited by this paper
• Target Preference of 15 Quinolones against Staphylococcus aureus, Based on Antibacterial Activities and Target Inhibition

  2001cited by this paper
• Staphylococcus aureus Mutants Selected by BMS-284756

  2001cited by this paper
• Mechanisms of action of antimicrobials: focus on fluoroquinolones.

  2001cited by this paper
• Inhibitors of Bacterial Topoisomerases: Mechanisms of Action and Resistance and Clinical Aspects1

  2001cited by this paper
• Gatifloxacin: a new fluoroquinolone

  2000cited by this paper
• Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms.

  2000cited by this paper
• Mechanisms of action and resistance of older and newer fluoroquinolones.

  2000cited by this paper
• A Dose-Response Study of Antibiotic Resistance in Pseudomonas aeruginosa Biofilms

  2000cited by this paper
• Mechanisms and Frequency of Resistance to Premafloxacin in Staphylococcus aureus: Novel Mutations Suggest Novel Drug-Target Interactions

  2000cited by this paper
• A Dose-Response Study of Antibiotic Resistance inPseudomonas aeruginosa Biofilms

  2000cited by this paper
• Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard

  2000cited by this paper
• Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard

  2000cited by this paper
• Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial.

  1999cited by this paper
• Antimicrobial activity of gatifloxacin tested against 1676 strains of ciprofloxacin-resistant gram-positive cocci isolated from patient infections in North and South America.

  1998cited by this paper
• Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.

  1997cited by this paper
• Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus

  1996cited by this paper
• Identification of a pKM101 region which confers a slow growth rate and interferes with susceptibility to quinolone in Escherichia coli AB1157

  1996cited by this paper
• Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus

  1996influential reference
• Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus

  1995cited by this paper
• Testing potential gyrase inhibitors of bacterial DNA gyrase: a comparison of the supercoiling inhibition assay and "cleavable complex" assay.

  1993cited by this paper
• A novel locus conferring fluoroquinolone resistance in Staphylococcus aureus

  1991cited by this paper
• Structure-activity relationship of quinolone antibacterial agents: the effects of C-2 substitution.

  1990cited by this paper
• Structure-activity relationships in quinolone antibacterials: design, synthesis and biological activities of novel isothiazoloquinolones.

  1988cited by this paper
• National Committee for Clinical Laboratory Standards.

  1980cited by this paper

• Azetidines in medicinal chemistry: emerging applications and approved drugs.

  2026cites this paper
• Isothiazolinones as preservatives: physicochemical characteristics, biological activity, and safety assessment

  2025cites this paper
• A new approach to overcoming antibiotic-resistant bacteria: Traditional Chinese medicine therapy based on the gut microbiota

  2023cites this paper
• Photoswitchable Antibiotic Hybrids: Spacer Length-Dependent Photochemical Control of Antibacterial Activity.

  2023cites this paper
• Moxifloxacin Liposomes: Effect of Liposome Preparation Method on Physicochemical Properties and Antimicrobial Activity against Staphylococcus epidermidis

  2022cites this paper
• Molecular Mechanisms of Drug Resistance in Staphylococcus aureus

  2022cites this paper
• Uptake of Ozenoxacin and Other Quinolones in Gram-Positive Bacteria

  2021cites this paper
• Single Molecule Non-cleavable Multiply Active Antibacterials

  2021cites this paper
• Enhanced antitubercular activity, alveolar deposition and macrophages uptake of mannosylated stable nanoliposomes

  2019cites this paper
• Investigating the genetic basis of preservative resistance in an industrial Pseudomonas aeruginosa strain

  2017cites this paper
• Identification of DNA gyrase Subunit a Mutations Associated with Ciprofloxacin Resistance in Staphylococcus aureus Isolated from Nasal Infection in Kurdistan-Iran

  2017influential citation
• Comparison of transcriptomes of wild-type and isothiazolone-resistant Pseudomonas aeruginosa by using RNA-seq

  2016cites this paper
• A “Double-Edged” Scaffold: Antitumor Power within the 
Antibacterial Quinolone

  2016cites this paper
• Insights into Pseudomonas aeruginosa ATCC9027 Resistance to Isothiazolones Through Proteomics

  2015cites this paper
• A Detailed Study of Antibacterial 3‐Acyltetramic Acids and 3‐Acylpiperidine‐2,4‐diones

  2014cites this paper
• Natural product inspired antibacterial tetramic acid libraries with dual enzyme inhibition

  2013cites this paper
• 7-Piperazinylquinolones with methylene-bridged nitrofuran scaffold as new antibacterial agents

  2013cites this paper
• New perspectives on antibacterial drug research

  2013cites this paper
• Involvement of outer membrane proteins and peroxide-sensor genes in Burkholderia cepacia resistance to isothiazolone

  2013cites this paper
• Prospects for developing new antibacterials targeting bacterial type IIA topoisomerases.

  2013cites this paper
• Recent Developments in Inhibitors of Bacterial Type IIA Topoisomerases

  2013cites this paper
• Novel quinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.

  2013cites this paper
• Structure aided design of chimeric antibiotics.

  2012cites this paper
• Bactericidal Activity of ACH-702 against Nondividing and Biofilm Staphylococci

  2012cites this paper
• Polypharmacology as an Emerging Trend in Antibacterial Discovery

  2012cites this paper
• Drug-resistant tuberculosis: emerging treatment options

  2011cites this paper
• Challenges of Antibacterial Discovery

  2011cites this paper
• In Vitro and In Vivo Profiles of ACH-702, an Isothiazoloquinolone, against Bacterial Pathogens

  2011influential citation
• In Vitro Antituberculosis Activities of ACH-702, a Novel Isothiazoloquinolone, against Quinolone-Susceptible and Quinolone-Resistant Isolates

  2010cites this paper
• In front of and behind the replication fork: bacterial type IIA topoisomerases

  2010cites this paper
• Quinolones: Action and Resistance Updated

  2009cites this paper
• Coevolution: mankind and microbes.

  2008cites this paper
• Recent advances in bacterial topoisomerase inhibitors.

  2008cites this paper
• Deciphering the mechanism of anti-bacterial activity of medicinal plant Ricinus communis L.

  year unknowncites this paper